CalciMedica IncNASDAQ:CALC
- LAST PRICE3.4900
- TODAY'S CHANGE (%)-0.0100 (-0.2857%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close3.5000 / 3.5000
- Day Range
- 52 Week Range
- Volume61,280
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CALC |
|---|---|---|
| 09:32 ET | 644 | 3.52 |
| 09:37 ET | 2225 | 3.4782 |
| 09:39 ET | 1500 | 3.4848 |
| 09:42 ET | 1400 | 3.4678 |
| 09:44 ET | 400 | 3.5 |
| 09:46 ET | 2321 | 3.4789 |
| 09:55 ET | 100 | 3.46 |
| 10:08 ET | 150 | 3.5088 |
| 10:09 ET | 600 | 3.48 |
| 10:20 ET | 500 | 3.505 |
| 10:22 ET | 200 | 3.48 |
| 10:24 ET | 200 | 3.51 |
| 10:26 ET | 100 | 3.51 |
| 10:27 ET | 228 | 3.51 |
| 10:29 ET | 2652 | 3.5 |
| 10:31 ET | 800 | 3.5 |
| 10:33 ET | 387 | 3.4678 |
| 10:36 ET | 100 | 3.49 |
| 10:38 ET | 200 | 3.5 |
| 10:40 ET | 100 | 3.51 |
| 10:44 ET | 100 | 3.52 |
| 10:45 ET | 100 | 3.51 |
| 11:02 ET | 3700 | 3.49 |
| 11:07 ET | 500 | 3.496 |
| 11:12 ET | 8300 | 3.5 |
| 11:20 ET | 118 | 3.52 |
| 11:23 ET | 5411 | 3.46 |
| 11:27 ET | 250 | 3.475 |
| 11:38 ET | 100 | 3.45 |
| 11:48 ET | 1111 | 3.45 |
| 11:57 ET | 520 | 3.45 |
| 11:59 ET | 1350 | 3.45 |
| 12:03 ET | 125 | 3.49 |
| 12:06 ET | 100 | 3.45 |
| 12:08 ET | 140 | 3.475 |
| 12:17 ET | 612 | 3.45 |
| 12:26 ET | 100 | 3.45 |
| 12:37 ET | 500 | 3.45 |
| 12:53 ET | 100 | 3.45 |
| 01:06 ET | 500 | 3.45 |
| 01:13 ET | 100 | 3.45 |
| 01:27 ET | 100 | 3.45 |
| 01:38 ET | 404 | 3.45 |
| 01:47 ET | 100 | 3.45 |
| 01:58 ET | 600 | 3.4566 |
| 02:07 ET | 200 | 3.45 |
| 02:18 ET | 300 | 3.47 |
| 02:21 ET | 300 | 3.45 |
| 02:25 ET | 290 | 3.4913 |
| 02:27 ET | 100 | 3.45 |
| 02:30 ET | 6268 | 3.43 |
| 02:32 ET | 100 | 3.45 |
| 02:45 ET | 100 | 3.42 |
| 02:56 ET | 524 | 3.41 |
| 03:08 ET | 100 | 3.41 |
| 03:26 ET | 100 | 3.42 |
| 03:32 ET | 100 | 3.42 |
| 03:33 ET | 254 | 3.45 |
| 03:46 ET | 1124 | 3.45 |
| 03:50 ET | 100 | 3.45 |
| 03:53 ET | 100 | 3.45 |
| 03:55 ET | 1100 | 3.49 |
| 04:00 ET | 3416 | 3.49 |
Nov 7, 2024
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
7:00AM ET on Thursday Nov 07, 2024 by Dow Jones*DJ CalciMedica Strengthens Leadership Team With Appointment Of Stephen Bardin As Chief Financial Officer >CALC, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 4, 2024
DJ CalciMedica Is Maintained at Buy by HC Wainwright & Co., from 7:11AM ET on Monday Nov 04, 2024 by Dow Jones
7:11AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 30, 2024
*DJ CalciMedica Announces Pricing of Public Offering of Common Stock, from 10:16PM ET on Wednesday Oct 30, 2024 by Dow Jones
10:16PM ET on Wednesday Oct 30, 2024 by Dow JonesCalciMedica Announces Pricing of Public Offering of Common Stock, from 10:11PM ET on Wednesday Oct 30, 2024 by Dow Jones
10:11PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CalciMedica Inc | 47.0M | -1.9x | --- |
OKYO Pharma Ltd | 36.5M | -1.5x | --- |
Immix Biopharma Inc | 47.2M | -2.0x | --- |
Intensity Therapeutics Inc | 46.7M | -3.1x | --- |
Xilio Therapeutics Inc | 47.5M | -0.5x | --- |
Rallybio Corp | 46.1M | -0.7x | --- |
Company Information
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).
Contact Information
- Headquarters
- 505 Coast Boulevard South, Suite 307LA JOLLA, CA, United States 92037
- Phone
- 858-952-5500
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Robert Wilson
- President, Chief Operating Officer
- Michael Dunn
- Chief Executive Officer, Director
- A. Rachel Leheny
- Chief Financial Officer
- Stephen Bardin
- Chief Scientific Officer
- Kenneth Stauderman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $47.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-1.88 |
Book Value | $1.43 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
